Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients

Anita S Iyer, Forrest K Jones, Ariana Nodoushani, Meagan Kelly, Margaret Becker, Damien Slater, Rachel Mills, Erica Teng, Mohammad Kamruzzaman, Wilfredo F Garcia-Beltran, Michael Astudillo, Diane Yang, Tyler E Miller, Elizabeth Oliver, Stephanie Fischinger, Caroline Atyeo, A John Iafrate, Stephen B Calderwood, Stephen A Lauer, Jingyou Yu, Zhenfeng Li, Jared Feldman, Blake M Hauser, Timothy M Caradonna, John A Branda, Sarah E Turbett, Regina C LaRocque, Guillaume Mellon, Dan H Barouch, Aaron G Schmidt, Andrew S Azman, Galit Alter, Edward T Ryan, Jason B Harris, Richelle C Charles, Anita S Iyer, Forrest K Jones, Ariana Nodoushani, Meagan Kelly, Margaret Becker, Damien Slater, Rachel Mills, Erica Teng, Mohammad Kamruzzaman, Wilfredo F Garcia-Beltran, Michael Astudillo, Diane Yang, Tyler E Miller, Elizabeth Oliver, Stephanie Fischinger, Caroline Atyeo, A John Iafrate, Stephen B Calderwood, Stephen A Lauer, Jingyou Yu, Zhenfeng Li, Jared Feldman, Blake M Hauser, Timothy M Caradonna, John A Branda, Sarah E Turbett, Regina C LaRocque, Guillaume Mellon, Dan H Barouch, Aaron G Schmidt, Andrew S Azman, Galit Alter, Edward T Ryan, Jason B Harris, Richelle C Charles

Abstract

We measured plasma and/or serum antibody responses to the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2 in 343 North American patients infected with SARS-CoV-2 (of which 93% required hospitalization) up to 122 days after symptom onset and compared them to responses in 1548 individuals whose blood samples were obtained prior to the pandemic. After setting seropositivity thresholds for perfect specificity (100%), we estimated sensitivities of 95% for IgG, 90% for IgA, and 81% for IgM for detecting infected individuals between 15 and 28 days after symptom onset. While the median time to seroconversion was nearly 12 days across all three isotypes tested, IgA and IgM antibodies against RBD were short-lived with median times to seroreversion of 71 and 49 days after symptom onset. In contrast, anti-RBD IgG responses decayed slowly through 90 days with only 3 seropositive individuals seroreverting within this time period. IgG antibodies to SARS-CoV-2 RBD were strongly correlated with anti-S neutralizing antibody titers, which demonstrated little to no decrease over 75 days since symptom onset. We observed no cross-reactivity of the SARS-CoV-2 RBD-targeted antibodies with other widely circulating coronaviruses (HKU1, 229 E, OC43, NL63). These data suggest that RBD-targeted antibodies are excellent markers of previous and recent infection, that differential isotype measurements can help distinguish between recent and older infections, and that IgG responses persist over the first few months after infection and are highly correlated with neutralizing antibodies.

Copyright © 2020, American Association for the Advancement of Science.

Figures

Fig. 1. Measurement of IgG, IgM, IgA…
Fig. 1. Measurement of IgG, IgM, IgA against SARS-CoV-2 spike protein receptor binding domain among pre-pandemic controls and PCR positive cases.
Each dot represents a unique measurement of an isotype (Row A: IgG, Row B: IgM, Row C: IgA) in pre-pandemic controls (left panels) and PCR positive cases (right panels). The blue line is a loess smooth nonparametric function. Black dashed lines indicate the maximum concentration (μg/mL) found among pre-pandemic controls (IgG: 0.57, IgM: 2.63, IgA: 2.02). Horizontal jitter was introduced into the pre-pandemic controls. The limit of detection (μg/mL) was 0.04 for IgG, 0.28 for IgM, and 0.30 for IgA.
Fig. 2. Parametric and nonparametric model estimates…
Fig. 2. Parametric and nonparametric model estimates of time to seroconversion and seroreversion for each isotype.
A) The isotype cut-offs chosen for seroconversion were the maximum concentration (μg/mL) found among pre-pandemic controls (IgG: 0.57, IgM: 2.63, IgA: 2.02). The solid line represents the estimated cumulative distribution function of the time to seroconversion or reversion with 100 bootstrapped fits shown as transparent lines. The parametric accelerated failure time models assume a log-normal time-to-event distribution. Nonparametric estimates shown in grey were calculated using the Turnbull method. Only 3 individuals seroreverted for IgG, so no model is included. B) The table indicates the estimated average number of days since onset of symptoms it takes for a percentage of cases to seroconvert or serorevert. Bootstrap 95% confidence intervals are shown in parentheses.
Fig. 3. SARS-CoV-2 pseudovirus neutralization antibody titers…
Fig. 3. SARS-CoV-2 pseudovirus neutralization antibody titers in symptomatic PCR positive cases and correlation with anti-RBD IgG responses.
A) Each point represents a measurement of 50% neutralizing titer (NT50). Lines connect measurements from the same individual and a loess smooth function is shown in blue. B) The overall repeated measures correlation coefficient (r) is shown. Lines represent simple linear models for each time period.

References

    1. Lipsitch M., Swerdlow D. L., Finelli L., Defining the Epidemiology of Covid-19 - Studies Needed. N. Engl. J. Med. 382, 1194–1196 (2020). 10.1056/NEJMp2002125
    1. WHO Coronavirus Disease (COVID-19) Dashboard. . Accessed 28th September,2020.
    1. Zohar T., Alter G., Dissecting antibody-mediated protection against SARS-CoV-2. Nat. Rev. Immunol. 20, 392–394 (2020). 10.1038/s41577-020-0359-5
    1. Döhla M., Boesecke C., Schulte B., Diegmann C., Sib E., Richter E., Eschbach-Bludau M., Aldabbagh S., Marx B., Eis-Hübinger A.-M., Schmithausen R. M., Streeck H., Rapid point-of-care testing for SARS-CoV-2 in a community screening setting shows low sensitivity. Public Health 182, 170–172 (2020). 10.1016/j.puhe.2020.04.009
    1. Huang A. T., Garcia-Carreras B., Hitchings M. D. T., Yang B., Katzelnick L. C., Rattigan S. M., Borgert B. A., Moreno C. A., Solomon B. D., Trimmer-Smith L., Etienne V., Rodriguez-Barraquer I., Lessler J., Salje H., Burke D. S., Wesolowski A., Cummings D. A. T., A systematic review of antibody mediated immunity to coronaviruses: Kinetics, correlates of protection, and association with severity. Nat. Commun. 11, 4704 (2020). 10.1038/s41467-020-18450-4
    1. Premkumar L., Segovia-Chumbez B., Jadi R., Martinez D. R., Raut R., Markmann A., Cornaby C., Bartelt L., Weiss S., Park Y., Edwards C. E., Weimer E., Scherer E. M., Rouphael N., Edupuganti S., Weiskopf D., Tse L. V., Hou Y. J., Margolis D., Sette A., Collins M. H., Schmitz J., Baric R. S., de Silva A. M., The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci. Immunol. 5, eabc8413 (2020). 10.1126/sciimmunol.abc8413
    1. Ren L., Fan G., Wu W., Guo L., Wang Y., Li X., Wang C., Gu X., Li C., Wang Y., Wang G., Zhou F., Liu Z., Ge Q., Zhang Y., Li H., Zhang L., Xu J., Wang C., Wang J., Cao B., Antibody Responses and Clinical Outcomes in Adults Hospitalized with Severe COVID-19: A Post hoc Analysis of LOTUS China Trial. Clin. Infect. Dis. ciaa1247 (2020). 10.1093/cid/ciaa1247
    1. McAndrews K. M., Dowlatshahi D. P., Dai J., Becker L. M., Hensel J., Snowden L. M., Leveille J. M., Brunner M. R., Holden K. W., Hopkins N. S., Harris A. M., Kumpati J., Whitt M. A., Lee J. J., Ostrosky-Zeichner L. L., Papanna R., LeBleu V. S., Allison J. P., Kalluri R., Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. JCI Insight 5, 142386 (2020).
    1. Gudbjartsson D. F., Norddahl G. L., Melsted P., Gunnarsdottir K., Holm H., Eythorsson E., Arnthorsson A. O., Helgason D., Bjarnadottir K., Ingvarsson R. F., Thorsteinsdottir B., Kristjansdottir S., Birgisdottir K., Kristinsdottir A. M., Sigurdsson M. I., Arnadottir G. A., Ivarsdottir E. V., Andresdottir M., Jonsson F., Agustsdottir A. B., Berglund J., Eiriksdottir B., Fridriksdottir R., Gardarsdottir E. E., Gottfredsson M., Gretarsdottir O. S., Gudmundsdottir S., Gudmundsson K. R., Gunnarsdottir T. R., Gylfason A., Helgason A., Jensson B. O., Jonasdottir A., Jonsson H., Kristjansson T., Kristinsson K. G., Magnusdottir D. N., Magnusson O. T., Olafsdottir L. B., Rognvaldsson S., le Roux L., Sigmundsdottir G., Sigurdsson A., Sveinbjornsson G., Sveinsdottir K. E., Sveinsdottir M., Thorarensen E. A., Thorbjornsson B., Thordardottir M., Saemundsdottir J., Kristjansson S. H., Josefsdottir K. S., Masson G., Georgsson G., Kristjansson M., Moller A., Palsson R., Gudnason T., Thorsteinsdottir U., Jonsdottir I., Sulem P., Stefansson K., Humoral Immune Response to SARS-CoV-2 in Iceland. N. Engl. J. Med. •••, (2020). 10.1056/NEJMoa2026116
    1. F. A. Ania Wajnberg, Adolfo Firpo, Deena Altman, Mark Bailey, Mayce Mansour, Meagan McMahon, Philip Meade, Damodara Rao Mendu, Kimberly Muellers, Daniel Stadlbauer, Kimberly Stone, Shirin Strohmeier, Judith Aberg, David Reich, Florian Krammer, Carlos Cordon-Cardo, SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. medRxiv (2020),
    1. Javier Ibarrondo F., Jennifer A., Fulcher, David Goodman-Meza, Julie Elliott, Christian Hofmann, Mary A. Hausner, Kathie G. Ferbas, Nicole H. Tobin, Grace M. Aldrovandi, Otto O. Yang, Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N. Engl. J. Med. (2020).
    1. Long Q.-X., Tang X.-J., Shi Q.-L., Li Q., Deng H.-J., Yuan J., Hu J.-L., Xu W., Zhang Y., Lv F. J., Su K., Zhang F., Gong J., Wu B., Liu X.-M., Li J.-J., Qiu J.-F., Chen J., Huang A.-L., Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 26, 1200–1204 (2020). 10.1038/s41591-020-0965-6
    1. Kucirka L. M., Lauer S. A., Laeyendecker O., Boon D., Lessler J., Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure. Ann. Intern. Med. 173, 262–267 (2020). 10.7326/M20-1495
    1. Guo L., Ren L., Yang S., Xiao M., Chang D., Yang F., Dela Cruz C. S., Wang Y., Wu C., Xiao Y., Zhang L., Han L., Dang S., Xu Y., Yang Q.-W., Xu S.-Y., Zhu H.-D., Xu Y.-C., Jin Q., Sharma L., Wang L., Wang J., Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin. Infect. Dis. 71, 778–785 (2020). 10.1093/cid/ciaa310
    1. Yong S. E. F., Anderson D. E., Wei W. E., Pang J., Chia W. N., Tan C. W., Teoh Y. L., Rajendram P., Toh M. P. H. S., Poh C., Koh V. T. J., Lum J., Suhaimi N. M., Chia P. Y., Chen M. I., Vasoo S., Ong B., Leo Y. S., Wang L., Lee V. J. M., Connecting clusters of COVID-19: An epidemiological and serological investigation. Lancet Infect. Dis. 20, 809–815 (2020).
    1. Antibody Test, Seen as Key to Reopening Country, Does Not Yet Deliver in The New York Times, (Published April 19, 2020).
    1. Antibody tests for Covid-19 wrong up to half the time, CDC in CNN. (May 26, 2020).
    1. Q. B. Zhen Zhang M, Shisong Fang, Lan Wei, Xin Wang, Jianfan He, Yongsheng Wu BS1, Xiaojian Liu MMed,Wei Gao MMed,Renli Zhang, Wenfeng Gong, Qiru Su,Andrew S Azman,Justin Lessler, Xuan Zou. (2020). Insights into the practical effectiveness of RT-PCR testing for SARS-CoV-2 from serologic data, a cohort study (2020). Published online September 08, 2020.
    1. Jae-Hoon Ko., Marcel A., Müller, Hyeri Seok, Ga Eun Park, Ji Yeon Lee, Sun Young Cho, Young Eun H, Jin Yang Baek, So Hyun Kim, Ji-Man Kang, Yae-Jean Kim, Ik Joon Jo, Chi Ryang Chung, Myong-Joon Hahn, Christian Drosten, Cheol-In Kang,a Doo Ryeon Chung, Jae-Hoon Song, Eun-Suk Kang, and Kyong Ran Peck, Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity. Diagn. Microbiol. Infect. Dis. 89, 106–111 (2017).
    1. Chandrashekar A., Liu J., Martinot A. J., McMahan K., Mercado N. B., Peter L., Tostanoski L. H., Yu J., Maliga Z., Nekorchuk M., Busman-Sahay K., Terry M., Wrijil L. M., Ducat S., Martinez D. R., Atyeo C., Fischinger S., Burke J. S., Slein M. D., Pessaint L., Van Ry A., Greenhouse J., Taylor T., Blade K., Cook A., Finneyfrock B., Brown R., Teow E., Velasco J., Zahn R., Wegmann F., Abbink P., Bondzie E. A., Dagotto G., Gebre M. S., He X., Jacob-Dolan C., Kordana N., Li Z., Lifton M. A., Mahrokhian S. H., Maxfield L. F., Nityanandam R., Nkolola J. P., Schmidt A. G., Miller A. D., Baric R. S., Alter G., Sorger P. K., Estes J. D., Andersen H., Lewis M. G., Barouch D. H., SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science 369, 812–817 (2020). 10.1126/science.abc4776
    1. R. A. D. Elena Criscuolo, Marta Strollo, Serena Rolla, Alessandro Ambrosi, Massimo Locatelli, Roberto Burioni, Nicasio Mancini, Massimo Clementi, Nicola Clementi, Poor correlation between antibody titers and neutralizing activity in sera from SARS-CoV-2 infected subjects. medRxiv (2020),
    1. Centers for Disease Control and Prevention, Interim Guidelines for COVID-19 Antibody Testing at . (2020). (2020). Accessed 27th, July 2020. (2020).
    1. M. Norman, T. Gilboa, A. F. Ogata, A. M. Maley, L. Cohen, Y. Cai, J. Zhang, J. E. Feldman, B. M. Hauser, T. M. Caradonna, B. Chen, A. G. Schmidt, G. Alter, R. C. Charles, E. T. Ryan, D. R. Walt, Ultra-Sensitive High-Resolution Profiling of Anti-SARS-CoV-2 Antibodies for Detecting Early Seroconversion in COVID-19 Patients. medRxiv, (2020), , Published online, May 02,2020.
    1. Wang C., Li W., Drabek D., Okba N. M. A., van Haperen R., Osterhaus A. D. M. E., van Kuppeveld F. J. M., Haagmans B. L., Grosveld F., Bosch B.-J., Publisher Correction: A human monoclonal antibody blocking SARS-CoV-2 infection. Nat. Commun. 11, 2511 (2020). 10.1038/s41467-020-16256-y
    1. Yu J., Tostanoski L. H., Peter L., Mercado N. B., McMahan K., Mahrokhian S. H., Nkolola J. P., Liu J., Li Z., Chandrashekar A., Martinez D. R., Loos C., Atyeo C., Fischinger S., Burke J. S., Slein M. D., Chen Y., Zuiani A., Lelis F. J. N., Travers M., Habibi S., Pessaint L., Van Ry A., Blade K., Brown R., Cook A., Finneyfrock B., Dodson A., Teow E., Velasco J., Zahn R., Wegmann F., Bondzie E. A., Dagotto G., Gebre M. S., He X., Jacob-Dolan C., Kirilova M., Kordana N., Lin Z., Maxfield L. F., Nampanya F., Nityanandam R., Ventura J. D., Wan H., Cai Y., Chen B., Schmidt A. G., Wesemann D. R., Baric R. S., Alter G., Andersen H., Lewis M. G., Barouch D. H., DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369, 806–811 (2020). 10.1126/science.abc6284
    1. Bryant J. E., Azman A. S., Ferrari M. J., Arnold B. F., Boni M. F., Boum Y., Hayford K., Luquero F. J., Mina M. J., Rodriguez-Barraquer I., Wu J. T., Wade D., Vernet G., Leung D. T., Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward. Sci. Immunol. 5, eabc6347 (2020). 10.1126/sciimmunol.abc6347
    1. C. Anderson-Bergman, icenReg: Regression Models for Interval Censored Data in R. (2017).

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera